百濟神州(06160.HK)第二季度產品收入增長120%至3.045億美元 研發費用達3.782億美元
格隆匯8月4日丨百濟神州(06160.HK)公佈,2022年第二季度,公司產品收入達3.045億美元,相較上一年同期的1.386億美元增長120%。2022年第二季度,百悦澤全球銷售額為1.287億美元,上一年同期數據為4,240萬美元;百澤安在中國的銷售額為1.049億美元,上一年同期數據為7,490萬美元。
截至2022年6月30日的三個月內,研發費用為3.782億美元,2021年同期數據為3.561億美元。研發費用的增加主要來自員工人數的增長,以及對藥物發現和臨牀開發投入的增加,包括在建立內部研究與臨牀開發能力方面的持續投入,其中部分與正在進行中的研發項目相關前期費用的減少所抵消。2022年第二季度和2021年第二季度,正在進行中的授權引入候選藥物研發相關預付款分別為0和4,500萬美元。此外,研發相關股權獎勵也帶來了研發費用的總體增長。截至2022年6月30日的三個月內,研發相關股權獎勵支出為3,710萬美元,2021年同期數據為3,020萬美元。
百濟神州聯合創始人、董事長兼首席執行官歐雷強(JohnV.Oyler)先生表示:“公司始終致力於為更多癌症患者提供可負擔的創新藥物,並不斷取得重要進展。在自主研發產品百悦澤和百澤安的推動下,公司商業化產品組合收入取得全面增長。如今,公司的創新藥物已在全球50多個市場獲得批准,其中百悦澤全球銷售額同比增長超過兩倍。公司將繼續在自主研發引擎的驅動下創造新機遇。公司將有望在今年下半年公佈百悦澤全球三期ALPINE臨牀試驗的最終分析數據,包括在慢性淋巴細胞白血病患者中的無進展生存期,以及百澤安用於一線治療不可切除肝細胞癌患者的主要數據”。
百濟神州首席財務官王愛軍(Julia Wang)女士表示:“憑藉在商業化產品組合和各地區業務的穩健發展勢頭,以及強勁的資本狀況,公司為未來的持續發展奠定了有利的優勢地位。公司將繼續推行嚴格的規範,並通過研發和商業化方面的戰略投資實現獲益”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.